Cisplatin and Cetuximab Treatment for Metastatic Cutaneous Squamous Cell Carcinoma: A Systematic Review

Abstract

Head-to-head prospective clinical studies between cetuximab and cisplatin are needed to determine which is more efficacious. In addition, prospective tumor registries and randomized controlled trials should be developed in order to establish the ideal systemic regimen in cSCC.

SLNB in cutaneous SCC: A review of the current state of literature and the direction for the future

“…In cases of distant metastasis, chemotherapy should be considered. EGRF inhibitors, such as cetuximab, have shown promising results in treatment of metastatic SCC with complete response rates of 67% and overall response rates of 78% …”

“…EGRF inhibitors, such as cetuximab, have shown promising results in treatment of metastatic SCC with complete response rates of 67% and overall response rates of 78%. 61 It is clear that SLNB should be in the discussion for every patient with "high-risk" SCC. A limitation in literature on this topic is that there is no concise, agreed-upon definition of what constitutes a "high-risk" SCC and many studies have failed to mention their selection of "high-risk" cases.…”

Cetuximab Treatment for Head and Neck Skin Cancer in a Patient with Heart Transplantation

“…All of the cetuximab treatment group had a drug-related acneiform rash. 15 Our patient received cetuximab in the third line setting, com-bined with 5-FU different from the literature. There were no serious adverse events except grade 3 leucopenia and grade 2 acneiform rashes which responsive to doxycycline.…”

Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death‐1 inhibitors: A review of the literature

“…Historically, the most frequent treatments included 5‐fluorouracil, cisplatin, carboplatin, or paclitaxel, alone or in combination (Martinez, Otley, Okuno, Foote, & Kasperbauer, ). As second‐line treatment, frequently target therapies with epidermal growth factor receptors (EGFR) inhibitors (i.e., cetuximab) are used (Trodello, Pepper, Wong, & Wysong, ). Immunologic therapies are new therapeutic strategies, but they are usually prescribed off‐label (Conforti, Corneli, Harwood, & Zalaudek, ).…”